ERNA-101
Platinum-Resistant Ovarian Cancer
PreclinicalActive Development
Key Facts
Indication
Platinum-Resistant Ovarian Cancer
Phase
Preclinical
Status
Active Development
Company
About Eterna Therapeutics
Eterna Therapeutics is advancing a pipeline of allogeneic, synthetic cell therapies targeting high-need areas in oncology and autoimmune diseases. The company's core technology engineers iPSC-derived mesenchymal stem cells (iMSCs) to function as targeted delivery vehicles for cytokines like IL-7/IL-15 and IL-10 directly to disease sites. With lead candidate ERNA-101 advancing towards the clinic for platinum-resistant ovarian cancer, the company's strategy focuses on demonstrating proof-of-concept in a challenging indication with significant unmet need, while leveraging a scalable platform for broader applications. Eterna operates as a public company, trading on the NASDAQ under the ticker ERNA.
View full company profileTherapeutic Areas
Other Platinum-Resistant Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Upifitamab rilsodotin (UpRi) | Mersana Therapeutics | Phase 3 |
| DT2216 | Dialectic Therapeutics | Phase 1/2 |
| MOv18 IgE | Epsilogen | Phase Ib |
| TTFields / INNOVATE-3 | Novocure | Phase 3 |